Inflammatory Disease
56
14
20
22
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
5.4%
3 terminated out of 56 trials
88.0%
+1.5% vs benchmark
5%
3 trials in Phase 3/4
18%
4 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (56)
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting
Impact of Supplementation With Synbiotics and Prebiotics on Cognitive Decline Associated With Neoadjuvant Chemotherapy in First-line Patients With Breast Cancer
Molecular Diagnosis of Systemic Autoinflammatory Diseases
68Gallium-FAPI46 PET/CT Imaging in Chronic Inflammatory and Fibrotic Diseases
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
Genetic Variants and Regulation of Specialized Pro-resolving Mediator
International T1 Multicenter Outcome Study
Biodistribution and Pathophysiology Study of 11C-para-aminobenzoic Acid
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
Personalized Therapies in Inflammatory Complex Disease
Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
Disease Characteristics of IR-CAD: a Case-control Study
Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe
Longevity Diet and the Fasting-mimicking Diet
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
A Dose Escalating Study of HC002 in Healthy Adult Volunteers